Search Results
1
Study Matches
A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Openlabel Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous (SC) Ustekinumab Maintenance in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis (UC)
The primary objective and primary endpoint in this study is to assess clinical remission.
participants who were in clinical response in induction.
To evaluate the safety profile of ustekinumab (study drug).
Participants who meet inclusion criteria will receive ustekinumab through and IntraVenous infusion during the induction period. And then will be randomized either every 8weeks or 12weeks to receive ustekinumab through a SubCutaneous injection.
Erica Miller at emiller25@pennstatehealth.psu.edu or 717-531-5656
All
Younger than 18 years old
NCT04630028
Digestive Systems & Liver Disease